Health (PRISME)

  • Presentation
  • Activities
  • Members
  • Publications

The PRISME team is composed of physicists, biochemists, biologists and radiotherapists. We specialize in multidisciplinary research aimed at developing, optimizing and controlling innovative radiotherapies, whether it be hadrontherapy or therapies using radioactive ion-emitting elements or nanoparticles. These radiotherapies aim to improve the treatment of certain cancers by increasing the effect of ionizing radiation in the tumor while minimizing its harmful effects on healthy tissues.

Our multidisciplinary approach aims to quantify, understand and predict the effect of ionizing radiation on living organisms from processes induced at extremely short times (attosecond) at small scales (atomic nucleus) to long-term consequences (years) at the patient level.
We therefore design and carry out irradiation experiments on targets ranging from molecules or cells to small animals and patient samples (tumor, blood). These experiments feed an important part of our activity which consists in modeling the effects of radiation on living organisms.

One of the innovative techniques of radiotherapy is hadrontherapy, which is to send
an ion beam on the tumors to destroy them. We are working, in particular using simulations, data processing and predictions, to improve these systems by having on-line control over irradiation using dedicated detectors. These tools also have applications in imaging.

The activities can be divided into three research areas:

Axis 1 aims to develop simulations and detectors to control patient irradiation by detecting the particles emitted during hadrontherapy treatment. These developments also offer application prospects in the field of diagnostic imaging.

Axis 2 focuses on the development of multi-scale models and simulations to describe and predict the physical, chemical and biological processes induced by irradiation. It also develops irradiation and dosimetric control means for the measurement of radiobiological effects.

Axis 3 quantifies by experiment the effects induced by irradiation with molecular, cellular, multicellular, in-vitro or in-vivo systems. It focuses on the specificities of innovative radiotherapies and the personalization of care.

PERMANENTS:

NON-PERMANENTS:

- DOCTORANTS / DOCTORAL STUDENTS:

- CHERCHEURS NON-PERMANENTS / NON-PERMANENT RESEARCHERS:
476 documents

  • V. Andreev, A. Baghdasaryan, K. Begzsuren, A. Belousov, A. Bolz, et al.. Determination of electroweak parameters in polarised deep-inelastic scattering at HERA. European Physical Journal C: Particles and Fields, 2018, 78 (9), pp.777. ⟨10.1140/epjc/s10052-018-6236-8⟩. ⟨hal-01846597⟩
  • Victor Mukhamedovich Abazov, Braden Keim Abbott, Bannanje Sripath Acharya, Mark Raymond Adams, Todd Adams, et al.. Measurement of the Effective Weak Mixing Angle in p\bar{p}\rightarrow Z/\gamma^* \rightarrow \ell^+\ell^- Events. Phys.Rev.Lett., 2018, 120 (24), pp.241802. ⟨10.1103/PhysRevLett.120.241802⟩. ⟨hal-01823317⟩
  • Victor Mukhamedovich Abazov, Braden Keim Abbott, Bannanje Sripath Acharya, Mark Raymond Adams, Todd Adams, et al.. Evidence for Z_c^{\pm}(3900) in semi-inclusive decays of b-flavored hadrons. Physical Review D, 2018, 98 (5), pp.052010. ⟨10.1103/PhysRevD.98.052010⟩. ⟨hal-01846814⟩
  • Riad Ladjohounlou, Claire Rodriguez-Lafrasse. Contribution des effets ciblĂ©s et non ciblĂ©s en radiothĂ©rapie vectorisĂ©e alpha/Auger et en radiothĂ©rapie externe. 13ème Congrès Francophone de Radiobiologie, Dec 2017, Lyon, France. ⟨hal-03133183⟩
  • Jean-Baptiste Guy, Sophie Espenel, Anne-Sophie Wozny, Priscillia Battiston-Montagne, Dominique Ardail, et al.. Ciblage des cellules souches cancĂ©reuses dans le cancer ORL: effet synergique du cetuximab Ă  l’ABT-199 en association Ă  l’irradiation photonique. 13ème Congrès Francophone de Radiobiologie, Dec 2017, Lyon, France. ⟨hal-02062244⟩
  • Alexandra Lauret, CĂ©line MalĂ©sys, Jonathan Lopez, Pierre Philouze, Philippe CĂ©ruse, et al.. Cellules Tumorales Circulantes : biomarqueurs prĂ©dictifs de l’échappement tumoral Ă  la radio(chimio)thĂ©rapie dans les cancers des VADS ?. SIRLAF: 13ème Congrès Francophone de Radiobiologie, Dec 2017, Lyon, France. ⟨hal-01738727⟩
  • Jean-Baptiste Guy, BenoĂ®te MĂ©ry, Edouard Ollier, Sophie Espenel, Alexis Vallard, et al.. Dual “mAb” HER family blockade in head and neck cancer human cell lines combined with photon therapy. Scientific Reports, 2017, 7 (1), pp.12207 - 12207. ⟨10.1038/s41598-017-12367-7⟩. ⟨hal-01609975⟩
  • Mattia Fontana, Denis Dauvergne, Jochen Krimmer, Jean Michel LĂ©tang, Jean-Luc Ley, et al.. Comparison between Anger and Compton cameras for medical imaging: a Monte Carlo simulation study. 2017 IEEE NSS/MIC/RTSD, Oct 2017, Atlanta, United States. 2017. ⟨hal-01609932⟩
  • Claire Rodriguez-Lafrasse, Marie-ThĂ©rèse Aloy, Jacqueline Sidi Boumedine, Shady Kotb, Lucie Sancey, et al.. AGuIX radiosensitizing nanoparticles: from molecular events to clinical applications. 63rd annual international meeting of Radiation Reaserach Society, Oct 2017, Cancun, Mexico. ⟨hal-01610963⟩
  • Anne-Sophie Wozny, Gersende Alphonse, Yannick Saintigny, MichaĂ«l Beuve, Claire Rodriguez-Lafrasse. A major contribution of the HIF-1α pathway in the oxygen effect. 63rd annual international meeting of Radiation Reaserach Society, Oct 2017, Cancun, Mexico. 2017. ⟨hal-01610972⟩

Powered by HAL logo